1. Home
  2. IHS vs HAE Comparison

IHS vs HAE Comparison

Compare IHS & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IHS Holding Limited

IHS

IHS Holding Limited

HOLD

Current Price

$8.17

Market Cap

2.8B

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$76.51

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHS
HAE
Founded
2001
1971
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical/Dental Instruments
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.8B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
IHS
HAE
Price
$8.17
$76.51
Analyst Decision
Buy
Buy
Analyst Count
6
9
Target Price
$8.29
$84.13
AVG Volume (30 Days)
1.3M
750.3K
Earning Date
05-19-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.05
Revenue
N/A
$910,373,000.00
Revenue This Year
$17.26
N/A
Revenue Next Year
$7.87
$5.23
P/E Ratio
$5.85
$36.26
Revenue Growth
N/A
N/A
52 Week Low
$5.71
$47.32
52 Week High
$8.95
$87.32

Technical Indicators

Market Signals
Indicator
IHS
HAE
Relative Strength Index (RSI) 43.13 58.24
Support Level $8.09 $72.04
Resistance Level $8.36 $80.90
Average True Range (ATR) 0.08 2.87
MACD -0.00 -0.39
Stochastic Oscillator 15.38 55.68

Price Performance

Historical Comparison
IHS
HAE

About IHS IHS Holding Limited

IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: